H5.010RSVTK

**H5.010RSVTK** is an investigational, replication-defective adenoviral gene-therapy vector that delivers the **herpes simplex virus thymidine kinase** transgene under control of the Rous sarcoma virus promoter. It was administered by stereotactic intratumoral injection for malignant brain tumors, followed by separately administered ganciclovir. Transduced tumor cells express HSV-TK, which converts ganciclovir into cytotoxic phosphorylated metabolites, creating a prodrug-activation or suicide-gene-therapy strategy intended to kill proliferating tumor cells. The vector was studied in Phase 1 trials in recurrent malignant glioma and advanced central nervous system malignancies. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00002824))

Other names

H5.010RSVtkH-5.010RSVtkH 5.010RSVtkAdv.RSVtk